<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797870</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1-14-010</org_study_id>
    <secondary_id>2020-003250-72</secondary_id>
    <nct_id>NCT05797870</nct_id>
  </id_info>
  <brief_title>Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)</brief_title>
  <acronym>Lip-Re2</acronym>
  <official_title>Efficacy Evaluation of 188Re-SSS Lipiodol Selective Internal Radiation Therapy of Non Operable Hepatocellular Carcinoma Patients, a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this monocentric interventional study is to evaluate the efficacy, in terms of&#xD;
      objective response rate, of the 188Re-SSS lipiodol SIRT in patients with non-operable HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-labelled treatment administration study conducted with an exact&#xD;
      one-stage one-arm study plan.&#xD;
&#xD;
      The study plans to included 35 patients and to treated 26 patients (take into account screen&#xD;
      failures and SIRT contraindications).&#xD;
&#xD;
      The treatment is delivered by a one-day procedure leading to the injection of 188Re-SSS&#xD;
      lipiodol. In details, the patient is hospitalized for one night. Two steps are performed&#xD;
      while the patient is hospitalized: the pre-treatment simulation step and the treatment step&#xD;
      itself.&#xD;
&#xD;
      After treatment, patients are followed until progression, new systemic or locoregional (in&#xD;
      the same treatment area) antineoplastic therapy or death, within a maximum 24-month period&#xD;
      following the SIRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2023</start_date>
  <completion_date type="Anticipated">December 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective response rate</measure>
    <time_frame>through study completion, an average of 4 year</time_frame>
    <description>Defined as the best overall response occurring within 6 months' post 188Re-SSS lipiodol injection according to the modified RECIST criteria for hepatocellular carcinoma</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>188Re-SSS lipiodol SIRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental arm will be treated with 188Re-SSS lipiodol Selective Internal Radiotherapy (SIRT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Selective Internal Radiation Therapy with 188Re-SSS lipiodol</intervention_name>
    <description>The treatment with 188Re-SSS lipiodol SIRT requires two steps during the patient's hospitalization: the pre-treatment simulation step and the treatment step itself.&#xD;
Pre-therapeutic simulation is performed during the screening phase, before definite patient inclusion, and is composed of two procedures: a diagnostic liver angiography and a liver perfusion scintigraphy (MAA scan and SPECT/CT).&#xD;
The therapeutic stage is also composed of two procedures a therapeutic liver angiography with 188Re-SSS lipiodol and a 188Re-SSS lipiodol SPECT/CT.</description>
    <arm_group_label>188Re-SSS lipiodol SIRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  ECOG Performance Status 0-1&#xD;
&#xD;
          -  HCC with histological diagnosis or non-invasive diagnosis according to AASLD criteria&#xD;
&#xD;
          -  Non operable and not accessible to ablation therapy&#xD;
&#xD;
          -  At least one measurable lesion using mRECIST&#xD;
&#xD;
          -  Tumor involvement &lt;50% of the liver&#xD;
&#xD;
          -  BCLC classification A to C&#xD;
&#xD;
          -  Compensated cirrhosis (Child Pugh A or B7), if cirrhosis present&#xD;
&#xD;
          -  Registration with a social security scheme&#xD;
&#xD;
          -  Written and informed consent of the patient or his/her legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate hematological, hepatic, renal, thyroid and coagulation functions:&#xD;
&#xD;
               1. Hemoglobin &lt; 8,5 g/dl&#xD;
&#xD;
               2. Granulocytes &lt; 1500/mm3&#xD;
&#xD;
               3. Platelets&lt; 50 000 /mm3&#xD;
&#xD;
               4. Bilirubin level ≥ 35 mol/l&#xD;
&#xD;
               5. Transaminases &gt; 6 UNL&#xD;
&#xD;
               6. Creatinine &gt; 1,5 UNL&#xD;
&#xD;
               7. TSH &lt; 0,2 µUI/L&#xD;
&#xD;
          -  Chronic respiratory insufficiency history&#xD;
&#xD;
          -  Extra-hepatic metastasis except hilum node &lt; 2 cm&#xD;
&#xD;
          -  Lung shunt &gt;20% evaluated with 99mTc albumin macroaggregate (MAA)&#xD;
&#xD;
          -  Poor tumor targeting with 99mTc albumin macroaggregate (MAA)&#xD;
&#xD;
          -  Previous SIRT&#xD;
&#xD;
          -  Previous systemic treatment within 4 weeks before radioembolization&#xD;
&#xD;
          -  More than 2 previous TACE (or embolization), in the area to be treated&#xD;
&#xD;
          -  Other neoplasia except if complete remission from at least one year&#xD;
&#xD;
          -  Contraindication related to the technique, in particular severe arterial pathology of&#xD;
             the lower limbs or the aorta contraindicating or making difficult an arteriography by&#xD;
             femoral approach&#xD;
&#xD;
          -  Pregnant woman or likely to be or breastfeeding, or male or female patients of&#xD;
             reproductive potential without effective contraception from screening to 1 month after&#xD;
             the end of the treatment&#xD;
&#xD;
          -  Minors, individual deprived of liberty, or under any kind of guardianship or&#xD;
             trusteeship.&#xD;
&#xD;
          -  Patients unable to submit to medical follow-up of the study for social, medical or&#xD;
             psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne Garin, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Lutte contre le Cancer Eugène Marquis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Trochet</last_name>
    <phone>02 99 25 31 65</phone>
    <phone_ext>+33</phone_ext>
    <email>m.trochet@rennes.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie Jolaine</last_name>
    <phone>02 99 25 30 36</phone>
    <phone_ext>+33</phone_ext>
    <email>v.jolaine@rennes.unicancer.fr</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selective Internal Radiation Therapy</keyword>
  <keyword>188Re-SSS lipiodol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

